On December 8, 2020, RayzeBio, a biotechnology company developing a broad pipeline of targeted radiopharmaceuticals against validated solid tumor targets, announced a $105 million Series B financing. Wilson Sonsini Goodrich & Rosati advised RayzeBio on intellectual property matters related to the financing.

The Series B financing was led by Venrock Healthcare Capital Partners alongside new investors OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments, and others. Also participating were existing investors from RayzeBio’s $45 million Series A financing, including venBio Partners, Versant Ventures, and Samsara BioCapital.

RayzeBio plans to use the two financings to advance multiple programs in parallel toward the clinic. The company also is expanding its headquarters in San Diego.

The Wilson Sonsini team advising RayzeBio on the related IP matters includes partner Michael Hostetler and associate Ying Chen.

Please see RayzeBio’s press release for more information.